文献速递MDS 与骨髓增殖性肿瘤

真性红细胞增多症与原发性血小板增多症中JAK2突变等位基因负荷降低的临床影响

Clinical impact of mutated JAK2 allele burden reduction in polycythemia vera and essential thrombocythemia.
PubMed 文献 · Am J Hematol · 2024-06-06

该前瞻性研究纳入77例接受芦可替尼中位8年治疗的真性红细胞增多症和原发性血小板增多症患者,动态监测JAK2与CALR变异等位基因频率(VAF)变化。末次观察时JAK2 VAF中位值由68%降至3.5%,20%患者达到深度持久分子学缓解,其与更长的完全临床血液学缓解持续时间及更低的骨髓纤维化进展率相关。

要点

  • 芦可替尼治疗中位8年,JAK2 VAF中位值由68%降至3.5%。
  • 20%患者达到深度持久分子学缓解,其中8%为完全分子学缓解。
  • 深度持久分子学缓解与更长的完全临床血液学缓解及更低的骨髓纤维化进展相关。

核心结论

  • 这些发现支持实现深度持久分子学缓解具有临床价值,并支持将其考虑作为未来临床试验的替代终点。

研究设计与样本

  • 前瞻性测量77例真性红细胞增多症和原发性血小板增多症患者接受芦可替尼(中位8年)治疗期间JAK2与CALR VAF的变化,并评估其与完全临床血液学缓解及结局的相关性。

主要发现

  • 末次观察时JAK2 VAF总体从中位68%(范围20%-99%)降至3.5%(0%-98%)。
  • 20%患者达到深度持久分子学缓解(VAF稳定≤2%),其中包括8%达到完全分子学缓解;25%达到部分分子学缓解(VAF较基线下降>50%);56%无分子学缓解。
  • 69%患者总体达到完全临床血液学缓解,且与所达到的任何程度分子学缓解无关;相反,深度持久分子学缓解与更长的完全临床血液学缓解持续时间相关,并与骨髓纤维化进展率降低及更长的无骨髓纤维化生存、无事件生存和无进展生存相关。
  • 与无分子学缓解相比,达到部分分子学缓解对结局也有一定有利影响。
  • 基线JAK2 VAF<50%以及治疗2年后VAF下降≥35%可预测深度持久分子学缓解的达成及骨髓纤维化进展减少。

关键数值与推荐

  • 深度持久分子学缓解定义为VAF稳定≤2%。
  • 部分分子学缓解定义为VAF较基线水平下降>50%。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

The variant allele frequency (VAF) of driver mutations (JAK2, CALR) in myeloproliferative neoplasms is associated with features of advanced disease and complications. Ruxolitinib and interferon were reported to variably reduce the mutant VAF, but the long-term impact of molecular responses (MR) remains debated. We prospectively measured changes in JAK2 and CALR VAF in 77 patients with polycythemia vera and essential thrombocythemia, treated with ruxolitinib for a median of 8 years, and assessed correlation with complete clinical and hematological response (CCHR) and outcomes. At last observation time, JAK2 VAF reduced overall from a median of 68% (range, 20%-99%) to 3.5% (0%-98%). A profound and durable MR (DMR; defined as a VAF stably ≤2%), including complete MR in 8%, was achieved in 20% of the patients, a partial MR (PMR; VAF reduction >50% of the baseline level) in 25%, and 56% had no molecular response (NMR). A CCHR was reached by 69% overall, independently of any degree of MR achieved; conversely, a DMR correlated with longer duration of CCHR and, most importantly, with reduced rate of progression to myelofibrosis and with longer myelofibrosis-free, event-free and progression-free survival. Achievement of PMR also had some favorable impact on outcomes, compared to NMR. A baseline JAK2 VAF <50%, and a VAF reduction of ≥35% after 2 years of treatment, predicted for the achievement of DMR and reduced progression to myelofibrosis. Overall, these findings support the clinical value of achieving profound, durable MR and its consideration as surrogate endpoint in future clinical trials.

来源:Am J Hematol,查看原文。版权归原作者所有。

引用

  1. Guglielmelli P, Mora B, Gesullo F, et al. Clinical impact of mutated JAK2 allele burden reduction in polycythemia vera and essential thrombocythemia. Am J Hematol. 2024. PMID: 38841874. doi:10.1002/ajh.27400

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。